A multicenter, randomized study of an extended cycle oral contraceptive

To assess the efficacy and safety of Seasonale®, 91-day extended cycle oral contraceptive (OC). A parallel, randomized, multicenter open-label, 1-year study of the OC Seasonale [30 μg ethinyl estradiol (EE)/150 μg levonorgestrel (LNG), and Nordette-28 (30 μg EE/150 μg LNG)] in sexually active, adult...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contraception (Stoneham) 2003-08, Vol.68 (2), p.89-96
Hauptverfasser: Anderson, F.D, Hait, Howard
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To assess the efficacy and safety of Seasonale®, 91-day extended cycle oral contraceptive (OC). A parallel, randomized, multicenter open-label, 1-year study of the OC Seasonale [30 μg ethinyl estradiol (EE)/150 μg levonorgestrel (LNG), and Nordette-28 (30 μg EE/150 μg LNG)] in sexually active, adult women (18–40 years) of childbearing potential. Patients received either four 91-day cycles of extended cycle regimen OC, or 13 cycles of the conventional 28-day OC with daily monitoring of compliance and bleeding via electronic diaries. When taken daily for 84 days followed by 7 days of placebo, the extended cycle regimen was effective in preventing pregnancy and had a safety profile that was comparable to that observed with the 28-day OC regimen that served as the control. While unscheduled (breakthrough) bleeding was reported among patients treated with the extended cycle regimen, it decreased with each successive cycle of therapy and was comparable to that reported by patients who received the conventional OC regimen by the fourth extended cycle This study demonstrated that Seasonale, 91-day extended cycle OC containing 84 days of 30 μg EE/150 μg LNG followed by 7 days of placebo, was effective, safe and well tolerated.
ISSN:0010-7824
1879-0518
DOI:10.1016/S0010-7824(03)00141-0